<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642278</url>
  </required_header>
  <id_info>
    <org_study_id>CR014587</org_study_id>
    <secondary_id>28431754DIA2001</secondary_id>
    <nct_id>NCT00642278</nct_id>
  </id_info>
  <brief_title>An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness, safety, and tolerability of
      JNJ-28431754 compared with placebo in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus is a metabolic disorder that is characterized by decreased secretion
      of insulin by the pancreas and resistance to the action of insulin in various tissues
      (muscle, liver, and adipose), which results in impaired glucose uptake. Chronic hyperglycemia
      leads to progressive impairment of insulin secretion and to insulin resistance of peripheral
      tissues in diabetes (so-called glucose toxicity), which further worsens control of blood
      glucose. In addition, chronic hyperglycemia is a major risk factor for complications,
      including heart disease, retinopathy, nephropathy, and neuropathy. Although numerous
      treatments have been developed for the treatment of diabetes and individual agents may be
      highly effective for some patients, it is still difficult to maintain optimal glycemic
      control in most patients with diabetes. This is a randomized, double-blind,
      placebo-controlled, parallel group, multicenter, dose-ranging study to determine the
      efficacy, safety and tolerability of JNJ-28431754 taken orally over 12 weeks, compared with
      placebo, in the treatment of Type 2 diabetes mellitus. The primary clinical hypothesis is
      that JNJ-28431754 is superior to placebo as measured by the change in hemoglobin A1c from
      baseline through Week 12 in the treatment of type 2 diabetes mellitus. Subject safety will be
      monitored throughout the study using spontaneous adverse event reporting, clinical laboratory
      tests (hematology, serum chemistry, urinalysis); severe and serious hypoglycemic episodes,
      assessment of urinary albumin excretion and markers of proximal renal tubular function;
      pregnancy tests; electrocardiograms (ECGs); vital sign measurements; physical examinations,
      assessment of calcium and phosphate homeostasis, bone formation and resorption markers, and
      hormones regulating calcium and phosphorus homeostasis; and vaginal and urine sample
      collection for fungal and bacterial culture in subjects with symptoms consistent with
      vulvovaginal candidiasis (VVC) or urinary tract infection (UTI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 12</measure>
    <time_frame>Day 1 (Baseline) and Week 12</time_frame>
    <description>The table below shows the mean change in HbA1c from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12</measure>
    <time_frame>Day 1 (Baseline) and Week 12</time_frame>
    <description>The table below shows the mean change in FPG from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Symptoms of Hypoglycemia</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The table below shows the percentage of patients who experienced symptomatic hypoglycemic events between Baseline and Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12</measure>
    <time_frame>Day 1 (Baseline) and Week 12</time_frame>
    <description>The table below shows the mean change in overnight urine glucose/creatinine ratio from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Body Weight From Baseline to Week 12</measure>
    <time_frame>Day 1 (Baseline) and Week 12</time_frame>
    <description>The table below shows the mean absolute change in body weight from Baseline to Week 12 for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight From Baseline to Week 12</measure>
    <time_frame>Day 1 (Baseline) and Week 12</time_frame>
    <description>The table below shows the mean percent change in body weight from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <condition>Diabetes Mellitus, Non Insulin Dependent</condition>
  <arm_group>
    <arm_group_label>Canagliflozin 50 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 100 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 200 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each patient will receive matching placebo twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin (JNJ-28431754)</intervention_name>
    <description>One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.</description>
    <arm_group_label>Canagliflozin 50 mg daily</arm_group_label>
    <arm_group_label>Canagliflozin 100 mg daily</arm_group_label>
    <arm_group_label>Canagliflozin 200 mg daily</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg daily</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg twice daily</arm_group_label>
    <other_name>JNJ-28431754</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.</description>
    <arm_group_label>Sitagliptin 100 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.</description>
    <arm_group_label>Canagliflozin 50 mg daily</arm_group_label>
    <arm_group_label>Canagliflozin 100 mg daily</arm_group_label>
    <arm_group_label>Canagliflozin 200 mg daily</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg daily</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg daily</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of type 2 diabetes mellitus

          -  Hemoglobin A1c levels &gt;=7% and &lt;=10.5%

          -  taking a stable daily dose of metformin

          -  Body mass index (BMI) 25 to 45 kg/m2 except those of Asian descent who must have a BMI
             of 24 to 45 kg/m2

          -  Stable body weight

          -  Serum creatinine &lt;=1.5 mg/dL (132.6 umol/L) for men and &lt;=1.4 mg/dL (123.76 umol/L)
             for women

        Exclusion Criteria:

          -  Patients must not have prior exposure or known contraindication or suspected
             hypersensitivity to canagliflozin (JNJ-28431754)

          -  Known contraindication or suspected hypersensitivity to sitagliptin or metformin

          -  A history of diabetic ketoacidosis or type 1 diabetes mellitus

          -  History of pancreas or beta-cell transplantation

          -  History of active proliferative diabetic retinopathy

          -  History of hereditary glucose-galactose malabsorption or primary renal glucosuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merced</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bueos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia N/A</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Romuald</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc 9</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisek 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 28</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kota Bharu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur N/A</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad De Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kutno 001</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce Pr</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <results_first_submitted>April 1, 2013</results_first_submitted>
  <results_first_submitted_qc>April 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 17, 2013</results_first_posted>
  <disposition_first_submitted>July 23, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>July 23, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Metformin</keyword>
  <keyword>Hemoglobin A1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study evaluated the efficacy and safety of canagliflozin (JNJ-28431754) in patients with type 2 diabetes mellitus with sitagliptin as a reference arm. The study was conducted between 27 March 2008 and 28 January 2009 and recruited patients from 85 study centers located in 13 countries worldwide.</recruitment_details>
      <pre_assignment_details>A total of 451 patients were randomly allocated to the 7 treatment arms in the study and comprised the intent-to-treat analysis set which was used for the efficacy analyses. All 451 patients received at least 1 dose of study drug and were included in the safety analysis set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Each patient received matching placebo twice daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Canagliflozin 50 mg Daily</title>
          <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="P3">
          <title>Canagliflozin 100 mg Daily</title>
          <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="P4">
          <title>Canagliflozin 200 mg Daily</title>
          <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="P5">
          <title>Canagliflozin 300 mg Daily</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="P6">
          <title>Canagliflozin 300 mg Twice Daily</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Sitagliptin 100 mg Daily</title>
          <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="64"/>
                <participants group_id="P7" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="57"/>
                <participants group_id="P7" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug regimen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Each patient received matching placebo twice daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Canagliflozin 50 mg Daily</title>
          <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="B3">
          <title>Canagliflozin 100 mg Daily</title>
          <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="B4">
          <title>Canagliflozin 200 mg Daily</title>
          <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="B5">
          <title>Canagliflozin 300 mg Daily</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="B6">
          <title>Canagliflozin 300 mg Twice Daily</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Sitagliptin 100 mg Daily</title>
          <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="64"/>
            <count group_id="B6" value="64"/>
            <count group_id="B7" value="65"/>
            <count group_id="B8" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="62"/>
                    <measurement group_id="B7" value="65"/>
                    <measurement group_id="B8" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="7.82"/>
                    <measurement group_id="B2" value="53.3" spread="8.48"/>
                    <measurement group_id="B3" value="51.7" spread="7.95"/>
                    <measurement group_id="B4" value="52.9" spread="9.56"/>
                    <measurement group_id="B5" value="52.3" spread="6.88"/>
                    <measurement group_id="B6" value="55.2" spread="7.14"/>
                    <measurement group_id="B7" value="51.7" spread="8.09"/>
                    <measurement group_id="B8" value="52.9" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region Enroll</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ARGENTINA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BULGARIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CZECH REPUBLIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAYSIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MEXICO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUSSIAN FEDERATION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 12</title>
        <description>The table below shows the mean change in HbA1c from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 12</time_frame>
        <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 50 mg Daily</title>
            <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 100 mg Daily</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 200 mg Daily</title>
            <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O6">
            <title>Canagliflozin 300 mg Twice Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg Daily</title>
            <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 12</title>
          <description>The table below shows the mean change in HbA1c from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
          <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="62"/>
                <count group_id="O7" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.702"/>
                    <measurement group_id="O2" value="-0.79" spread="0.749"/>
                    <measurement group_id="O3" value="-0.76" spread="0.992"/>
                    <measurement group_id="O4" value="-0.70" spread="0.720"/>
                    <measurement group_id="O5" value="-0.92" spread="0.695"/>
                    <measurement group_id="O6" value="-0.95" spread="0.704"/>
                    <measurement group_id="O7" value="-0.74" spread="0.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted using Dunnett's procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.747</ci_lower_limit>
            <ci_upper_limit>-0.148</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted using Dunnett's procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.804</ci_lower_limit>
            <ci_upper_limit>-0.207</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted using Dunnett's procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.841</ci_lower_limit>
            <ci_upper_limit>-0.244</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted using Dunnett's procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.117</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.006</ci_lower_limit>
            <ci_upper_limit>-0.405</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted using Dunnett's procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.029</ci_lower_limit>
            <ci_upper_limit>-0.432</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted using Dunnett's procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.862</ci_lower_limit>
            <ci_upper_limit>-0.265</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12</title>
        <description>The table below shows the mean change in FPG from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 12</time_frame>
        <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 50 mg Daily</title>
            <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 100 mg Daily</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 200 mg Daily</title>
            <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O6">
            <title>Canagliflozin 300 mg Twice Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg Daily</title>
            <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12</title>
          <description>The table below shows the mean change in FPG from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
          <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="62"/>
                <count group_id="O7" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.58"/>
                    <measurement group_id="O2" value="-0.9" spread="2.26"/>
                    <measurement group_id="O3" value="-1.4" spread="1.70"/>
                    <measurement group_id="O4" value="-1.5" spread="2.23"/>
                    <measurement group_id="O5" value="-1.4" spread="1.87"/>
                    <measurement group_id="O6" value="-1.3" spread="1.54"/>
                    <measurement group_id="O7" value="-0.7" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.98</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>-1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>-1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>-1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Symptoms of Hypoglycemia</title>
        <description>The table below shows the percentage of patients who experienced symptomatic hypoglycemic events between Baseline and Week 12.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomiy assigned to a treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 50 mg Daily</title>
            <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 100 mg Daily</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 200 mg Daily</title>
            <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O6">
            <title>Canagliflozin 300 mg Twice Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg Daily</title>
            <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Symptoms of Hypoglycemia</title>
          <description>The table below shows the percentage of patients who experienced symptomatic hypoglycemic events between Baseline and Week 12.</description>
          <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomiy assigned to a treatment group.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12</title>
        <description>The table below shows the mean change in overnight urine glucose/creatinine ratio from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 12</time_frame>
        <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 50 mg Daily</title>
            <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 100 mg Daily</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 200 mg Daily</title>
            <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O6">
            <title>Canagliflozin 300 mg Twice Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg Daily</title>
            <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12</title>
          <description>The table below shows the mean change in overnight urine glucose/creatinine ratio from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
          <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
          <units>mg/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="12.34"/>
                    <measurement group_id="O2" value="35.4" spread="28.98"/>
                    <measurement group_id="O3" value="51.5" spread="28.83"/>
                    <measurement group_id="O4" value="50.5" spread="24.38"/>
                    <measurement group_id="O5" value="49.4" spread="38.41"/>
                    <measurement group_id="O6" value="61.6" spread="37.85"/>
                    <measurement group_id="O7" value="-1.9" spread="14.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>36.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.07</ci_lower_limit>
            <ci_upper_limit>46.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>49.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.17</ci_lower_limit>
            <ci_upper_limit>59.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>48.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.98</ci_lower_limit>
            <ci_upper_limit>58.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>49.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>38.91</ci_lower_limit>
            <ci_upper_limit>59.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>60.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.17</ci_lower_limit>
            <ci_upper_limit>70.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.513</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.33</ci_lower_limit>
            <ci_upper_limit>6.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Body Weight From Baseline to Week 12</title>
        <description>The table below shows the mean absolute change in body weight from Baseline to Week 12 for each treatment group.</description>
        <time_frame>Day 1 (Baseline) and Week 12</time_frame>
        <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 50 mg Daily</title>
            <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 100 mg Daily</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 200 mg Daily</title>
            <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O6">
            <title>Canagliflozin 300 mg Twice Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg Daily</title>
            <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Body Weight From Baseline to Week 12</title>
          <description>The table below shows the mean absolute change in body weight from Baseline to Week 12 for each treatment group.</description>
          <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="62"/>
                <count group_id="O7" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="2.099"/>
                    <measurement group_id="O2" value="-1.96" spread="2.334"/>
                    <measurement group_id="O3" value="-2.25" spread="2.145"/>
                    <measurement group_id="O4" value="-2.32" spread="2.842"/>
                    <measurement group_id="O5" value="-2.88" spread="2.391"/>
                    <measurement group_id="O6" value="-2.87" spread="2.344"/>
                    <measurement group_id="O7" value="-0.43" spread="2.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight From Baseline to Week 12</title>
        <description>The table below shows the mean percent change in body weight from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 12</time_frame>
        <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 50 mg Daily</title>
            <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 100 mg Daily</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 200 mg Daily</title>
            <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
          <group group_id="O6">
            <title>Canagliflozin 300 mg Twice Daily</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg Daily</title>
            <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight From Baseline to Week 12</title>
          <description>The table below shows the mean percent change in body weight from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.</description>
          <population>This analysis was conducted using the intent-to-treat analysis set, which included all patients who were randomly assigned to a treatment group. The last-observation-carried-forward method was applied when Week 12 values were missing. The table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="62"/>
                <count group_id="O7" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.4"/>
                    <measurement group_id="O2" value="-2.3" spread="2.8"/>
                    <measurement group_id="O3" value="-2.6" spread="2.3"/>
                    <measurement group_id="O4" value="-2.7" spread="3.0"/>
                    <measurement group_id="O5" value="-3.4" spread="2.8"/>
                    <measurement group_id="O6" value="-3.4" spread="2.6"/>
                    <measurement group_id="O7" value="-0.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and mixed meal tolerance test.</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>-2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>-2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline value, and stratification factor (participation in mixed meal tolerance test).</method_desc>
            <param_type>Least-Sqaures Mean Difference</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported for the duration of the study; each patient participated in the study for approximately 12 weeks.</time_frame>
      <desc>The total number of adverse events listed in the &quot;Other (non-Serious) Adverse Event&quot; table are based upon a cut-off of greater than or equal to 5 percent of patients experiencing the adverse event in any treatment arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Each patient received matching placebo twice daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Canagliflozin 50 mg Daily</title>
          <description>Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="E3">
          <title>Canagliflozin 100 mg Daily</title>
          <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="E4">
          <title>Canagliflozin 200 mg Daily</title>
          <description>Each patient received 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="E5">
          <title>Canagliflozin 300 mg Daily</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
        <group group_id="E6">
          <title>Canagliflozin 300 mg Twice Daily</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Sitagliptin 100 mg Daily</title>
          <description>Each patient received 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Franchise Medical Leader, Cardiovascular &amp; Metabolism Franchise</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>1-800-526-7736</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

